Clinical Trial: Cytokine Profiles in Spondylodiscitis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Verification and Progress of Cytokine Profiles for the Discrimination of Infectious and Non-infectious, Degenerative Diseases of the Spine

Brief Summary:

Spondylodiscitis is an infectious disease of the intervertebral discs and adjacent vertebral bodies, which often has a protracted progression. Diagnosis is frequently delayed because of the unspecific pathology and a lack of specific infection markers. However, an early diagnosis is fundamental to prevent long periods with symptoms including extensive back pain and progressive and destructive changes of the spine.

Cytokines can be helpful to extend the knowledge about diverse biological processes. Furthermore, they are a promising category of biomarkers that are already present in the early phases of developing diseases. Currently, little is known about the participation of cytokines in Spondylodiscitis. The aim of this study is to establish a non-invasive method to improve the diagnosis of spondylodiscitis. Therefore, blood and tissue samples will be analyzed at different time points for the concentration of specific cytokines to select potential marker cytokines via a Multiplex Assay. After successful identification of marker cytokines, verification of the results will be done by expression analysis of cytokine-producing cells.

The potential of such a diagnostic method lies in reducing medical costs and preventing extensive pain and structural changes of the spine.

Experimental research will be performed with the approval of the ethic committee of the medical faculty of the University of Cologne.


Detailed Summary:

Spondylodiscitis is a primary infection of the intervertebral discs with secondary infection of the adjacent end-plates and vertebral bodies. It is relatively rare with an incidence of 2.4:100.000 and three times more common among men. The process of infection, which is commonly creeping, leads to a destruction of the vertebral bodies and production of abscesses, which can cause neurological deficits.

Clinical symptoms, especially in the early stages, are uncommon. Patients suffer from unspecific back pain and fever occurs only in 50% of all cases. Currently, markers used including leucocyte count, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are also unspecific.For this reason of that several weeks may elapse between the first signs of symptoms and the final diagnosis of spondylodiscitis. Therefore, the identification of the pathogen is indispensable for an effective antibiotic therapy.

Spinal infections are generally monomicrobial, frequently with a haematogenous source. Therefore, blood cultures can be used for identifying the pathogens. In case of negative blood cultures, the pathogens can be identified by invasive methods such as percutaneous punch biopsy or CT-guided fine needle aspiration. Despite biopsies, the pathogen can only be identified in two out of three patients. Failures of pathogen identification are mainly due to previous systemic antibiotic treatment. As a consequence, diagnosis is often based on medical imaging methods (CT, MRT, PET, radiograph, skeletal scintigraphy). The disadvantage of these methods is that structural changes of the spine must occur to become visible.

Treatment of an advanced spondylodiscitis consists of removal of the necrotic tissue, stabilization of the affected vertebral bodies and concomitant antibiotic ther
Sponsor: University of Cologne

Current Primary Outcome: Number of patients with high cytokine profiles as a measurement for the diagnosis of spondylodiscitis [ Time Frame: Change from Baseline in different Cytokine profiles to 3 month after surgery ]

different cytokine profiles between groups


Original Primary Outcome: Same as current

Current Secondary Outcome: Number of patients with high cytokine profiles as a measurement for the diagnosis of spondylodiscitis [ Time Frame: Change from Baseline in different Cytokine profiles to 3 month after surgery ]

cytokines in tissues/cells


Original Secondary Outcome: Same as current

Information By: University of Cologne

Dates:
Date Received: September 15, 2015
Date Started: October 2015
Date Completion: June 2017
Last Updated: February 16, 2017
Last Verified: February 2017